Rocket Lab (NASDAQ: RKLB) is facing tightening financial assumptions after updated analyst models trimmed its net profit margin forecast from approximately 8.41% to roughly 7.79%.
That margin revision, paired with a delay in the company’s Neutron rocket program to 2027, has driven a roughly 3% reduction in consensus fair value estimates for the stock.
The revised fair value now sits at approximately $102.15, down from a prior figure of around $105.05, reflecting updated assumptions on timing and profitability across several business lines.
Among the firms cutting their price targets are Goldman Sachs, Citizens, KeyBanc, TD Cowen, Roth Capital, and Clear Street, each citing execution risk tied to the Neutron delay and rising near-term costs.
Goldman Sachs issued the starkest assessment, explicitly modeling higher cash burn over the coming quarters and identifying the Neutron program, along with the pending Iridium and Mynaric acquisitions, as sources of integration and margin risk.
The Neutron delay is particularly significant because the reusable medium-lift rocket has been central to Rocket Lab’s long-term revenue growth thesis and its ambitions in national security launch markets.
Roth Capital and Clear Street offered a more measured reading of the setback, framing the timeline shift as a deliberate decision to prioritize process quality over speed rather than a retreat from the company’s medium-lift ambitions.
On the bullish side, firms including Citi, Berenberg, Barclays, Cantor Fitzgerald, and Raymond James continue to highlight Rocket Lab’s vertically integrated platform spanning launch vehicles and satellite systems as a structural competitive advantage.
Roth Capital and Cantor Fitzgerald point to a multi-billion dollar backlog and significant program wins in space systems as evidence that revenue visibility remains intact even as the Neutron schedule shifts.
Clear Street and Stifel separately see the pending Iridium acquisition as a vehicle to deepen Rocket Lab’s exposure to national security contracts, potentially opening pathways to programs such as SDA constellation work and the Golden Dome initiative.
Beneath the price target debate, the updated financial model reveals subtle but telling adjustments, with projected revenue growth edging down from approximately 37.00% to roughly 36.82%, and the discount rate trimmed from about 7.98% to 7.87%.
Perhaps the most striking figure in the revised framework is the implied future price-to-earnings multiple, which has expanded from an already elevated 583x to approximately 612x, underscoring how much of Rocket Lab’s valuation rests on long-range execution rather than near-term earnings.
The dual acquisition burden of integrating both Iridium and Mynaric simultaneously amplifies the execution challenge, with Goldman Sachs flagging both deals as potential pressure points on margins at a time when R&D and capital spending remain elevated.
Rocket Lab’s Electron launch cadence and in-house satellite production capabilities remain core to the bull case, with supporters arguing that vertical integration positions the company for larger defense contracts as the commercial space sector matures.
